

02 Jun 2016 |

# INFOGRAPHIC: Immuno-Oncology Targets And Deal Trends

by Mandy Jackson

Immuno-oncology R&D is surging, though most programs still are in preclinical studies or early clinical trials. Even so, dealmaking is thriving and generating lucrative terms compared with cancer deals in general as big pharma and large biotech companies look for the safest and most effective IO drug combinations.






## MUNO-ONCOLOGY

### **Key Targets And Deal Facts**

Immuno-oncology is one of the most active areas of drug development with companies small and large racing to bring new therapies into the clinic that address the hottest targets in cancer treatment – enthusiasm reflected by the number of firms entering into IO deals.

#### key immuno-oncology drug targets

(PD-1/PD-L1, CTLA4, GM-CSF/GM-CSFR, LAG3, TIM3, TLR, IDO, CD40, CD47 and OX40)




#### therapeutic candidates:

5 have been approved

**39** are in the clinic

55 are preclinical<sup>1</sup>

The largest immuno-oncology category is therapeutic candidates that target PD-1 or **PD-L1** with **37** compounds in development.<sup>2</sup>



**3** approved biologics **23** preclinical assets



11 in the clinic

#### Stages of development for all 10 drug classes reviewed<sup>3</sup>

Target	Preclinical	Phase I	Phase I/II	Phase II	Phase II/II	Phase III*
http://scrip.citeline.co PD-1 / PD-L1 <sup>(1)</sup> © Citeline 2024. All rig	m/SC065312 <b>23</b> hts reserved.	6	2	1		2
CTLA492 <sup>(2)</sup>	5	1		1		